Cargando…

Gastrointestinal Incretins—Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) beyond Pleiotropic Physiological Effects Are Involved in Pathophysiology of Atherosclerosis and Coronary Artery Disease—State of the Art

SIMPLE SUMMARY: The presented manuscript contains the most current and extensive summary of the role of the most predominant gastrointestinal hormones—GIP and GLP-1 in the pathophysiology of atherosclerosis and coronary artery disease both in animals and humans. We have described GIP and GLP-1 as (1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jonik, Szymon, Marchel, Michał, Grabowski, Marcin, Opolski, Grzegorz, Mazurek, Tomasz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8869592/ https://www.ncbi.nlm.nih.gov/pubmed/35205155 http://dx.doi.org/10.3390/biology11020288

Ejemplares similares

Nephroprotective Properties of the Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) Receptor Agonists
por: Bulum, Tomislav
Publicado: (2022)

Investigation of endothelial nitric oxide (NO) signalling in response to the incretin hormone glucose-dependent insulinotropic polypeptide (GIP)
por: Savage, PJ, et al.
Publicado: (2012)

Glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1: Incretin actions beyond the pancreas
por: Seino, Yutaka, et al.
Publicado: (2013)

The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect
por: Fisman, Enrique Z., et al.
Publicado: (2021)

Serum Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) in association with the Risk of Gestational Diabetes: A Prospective Case-Control Study
por: Mosavat, Maryam, et al.
Publicado: (2020)

GIP and GLP‐1, the two incretin hormones: Similarities and differences
por: Seino, Yutaka, et al.
Publicado: (2010)

The Incretin Effect in Female Mice With Double Deletion of GLP-1 and GIP Receptors
por: Ahrén, Bo, et al.
Publicado: (2019)

The Incretins and Pancreatic β-Cells: Use of Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide to Cure Type 2 Diabetes Mellitus
por: Kim, Mi-Hyun, et al.
Publicado: (2010)

Glucose-dependent insulinotropic polypeptide (GIP) and GIP receptor (GIPR) genes: An association analysis of polymorphisms and bone in young and elderly women
por: Garg, Gaurav, et al.
Publicado: (2015)

GIP: An Inconsequential Incretin or Not?
por: Pratley, Richard E.
Publicado: (2010)

Glucose-dependent Insulinotropic Polypeptide (GIP) Resistance and β-cell Dysfunction Contribute to Hyperglycaemia in Acromegaly
por: Shekhawat, Vikram Singh, et al.
Publicado: (2019)

Glucose-Dependent Insulinotropic Polypeptide (GIP) Reduces Bone Resorption in Patients With Type 2 Diabetes
por: Christensen, Mikkel B, et al.
Publicado: (2020)

Incretin concept revised: The origin of the insulinotropic function of glucagon‐like peptide‐1 – the gut, the islets or both?
por: Yabe, Daisuke, et al.
Publicado: (2017)

SAT037 Glucagon-like Peptide-1 Receptor Knockout Mice Do Not Compensate For The Lack Of Incretin Action By Increasing Glucose-dependent Insulinotropic Polypeptide Secretion
por: Douglas Galsgaard, Katrine, et al.
Publicado: (2023)

Role of a Dual Glucose-Dependent Insulinotropic Peptide (GIP)/Glucagon-like Peptide-1 Receptor Agonist (Twincretin) in Glycemic Control: From Pathophysiology to Treatment
por: Pelle, Maria Chiara, et al.
Publicado: (2021)

Mechanisms underlying glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 secretion
por: Reimann, Frank, et al.
Publicado: (2016)

Carbohydrate‐induced secretion of glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1
por: Seino, Yusuke, et al.
Publicado: (2016)

The effect of glucose-dependent insulinotropic polypeptide (GIP) variants on visceral fat accumulation in Han Chinese populations
por: Wang, T, et al.
Publicado: (2017)

The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion—A Review
por: Mathiesen, David S., et al.
Publicado: (2019)

The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling
por: Zhang, Qian, et al.
Publicado: (2021)

Administration of Jerusalem artichoke reduces the postprandial plasma glucose and glucose-dependent insulinotropic polypeptide (GIP) concentrations in humans
por: Takahashi, Hirokazu, et al.
Publicado: (2022)

Glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 secretion in humans: Characteristics and regulation
por: Alsalim, Wathik, et al.
Publicado: (2022)

Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice
por: Jall, Sigrid, et al.
Publicado: (2017)

Dysglycemia Shapes Visceral Adipose Tissue’s Response to GIP, GLP-1 and Glucagon in Individuals with Obesity
por: Morais, Tiago, et al.
Publicado: (2023)

GIP_HUMAN [22–51] Peptide Encoded by the Glucose-Dependent Insulinotropic Polypeptide (GIP) Gene Suppresses Insulin Expression and Secretion in INS-1E Cells and Rat Pancreatic Islets
por: Pusch, Emily, et al.
Publicado: (2023)

Incretin Receptor Null Mice Reveal Key Role of GLP-1 but Not GIP in Pancreatic Beta Cell Adaptation to Pregnancy
por: Moffett, R. Charlotte, et al.
Publicado: (2014)

Over-expression, purification and isotopic labeling of a tag-less human glucose-dependent insulinotropic polypeptide (hGIP)
por: Chandarana, Rakesh C., et al.
Publicado: (2013)

Sitagliptin decreases ventricular arrhythmias by attenuated glucose-dependent insulinotropic polypeptide (GIP)-dependent resistin signalling in infarcted rats
por: Lee, Tsung-Ming, et al.
Publicado: (2016)

An Individualized Approach of Multidisciplinary Heart Team for Myocardial Revascularization and Valvular Heart Disease—State of Art
por: Jonik, Szymon, et al.
Publicado: (2022)

ADGRL3 genomic variation implicated in neurogenesis and ADHD links functional effects to the incretin polypeptide GIP
por: Vidal, Oscar M., et al.
Publicado: (2022)

The novel dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 (GLP‐1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long‐acting GLP‐1 receptor agonists
por: Urva, Shweta, et al.
Publicado: (2020)

Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors
por: Zhao, Fenghui, et al.
Publicado: (2022)

Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice
por: Knerr, Patrick J., et al.
Publicado: (2022)

A Physiologically‐Based Quantitative Systems Pharmacology Model of the Incretin Hormones GLP‐1 and GIP and the DPP4 Inhibitor Sitagliptin
por: Balazki, Pavel, et al.
Publicado: (2020)

Attenuated secretion of glucose-dependent insulinotropic polypeptide (GIP) does not alleviate hyperphagic obesity and insulin resistance in ob/ob mice
por: Shimazu-Kuwahara, Satoko, et al.
Publicado: (2017)

The Effect of Exogenous Glucose-Dependent Insulinotropic Polypeptide in Combination With Glucagon-Like Peptide-1 on Glycemia in the Critically Ill
por: Lee, Michael Y., et al.
Publicado: (2013)

The Cardiovascular Effect of Tirzepatide: A Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide Dual Agonist
por: Cho, Yun Kyung, et al.
Publicado: (2023)

Pleiotropic effects of incretins
por: Gupta, Vishal
Publicado: (2012)

N‐terminally and C‐terminally truncated forms of glucose‐dependent insulinotropic polypeptide are high‐affinity competitive antagonists of the human GIP receptor
por: Hansen, L S, et al.
Publicado: (2016)

Genetically Predicted Glucose-Dependent Insulinotropic Polypeptide (GIP) Levels and Cardiovascular Disease Risk Are Driven by Distinct Causal Variants in the GIPR Region
por: Bowker, Nicholas, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7m986nbrbvafljanvavl2ormqc